Book contents
- Seminars in Clinical Psychopharmacology
- College Seminars Series
- Seminars in Clinical Psychopharmacology
- Copyright page
- Contents
- Contributors
- Foreword
- Preface
- Editor’s Note on Nomenclature
- Neuroscience-Based Nomenclature Glossary
- Abbreviations
- Part 1 Basic Science and General Principles
- Part 2 Psychopharmacology of the Main Psychotropic Drug Groups
- Chapter 7 Drugs to Treat Depression
- Chapter 8 Drugs to Treat Anxiety and Insomnia
- Chapter 9 Drugs to Treat Schizophrenia and Psychosis (Dopamine Antagonists and Partial Agonists Other Than Clozapine)
- Chapter 10 Clozapine
- Chapter 11 Lithium
- Chapter 12 Anticonvulsants for Mental Disorders: Valproate, Lamotrigine, Carbamazepine and Oxcarbazepine
- Chapter 13 Drugs to Treat Attention Deficit Hyperactivity Disorder (ADHD)
- 13.1 Introduction
- 13.2 History of Drugs Used to Treat ADHD
- 13.3 Pharmacology and Mechanisms of Action
- 13.4 Legal Status and Licensing of Drugs for Treating ADHD
- 13.5 Writing Prescriptions for Stimulants in the UK
- 13.6 Shared Decision Making/Psychoeducation
- 13.7 Efficacy of Drug Treatment
- 13.8 New Drugs on the ADHD Portfolio
- 13.9 Longer-Term Use of Medications
- 13.10 Placebo Effects in RCTs and Clinical Practice
- 13.11 Adverse Effects of ADHD Medicines and Monitoring
- 13.12 Prescribing Recommendations in ADHD Guidelines
- 13.13 Personalized Drug Selection, Titration and Dose Regimens
- 13.14 Adherence to Medication, Drug Holidays and Flexible Dosing
- 13.15 Annual Review of Medication
- 13.16 Treating ADHD with Co-morbid Disorders
- 13.17 ADHD in Specific Populations
- 13.18 ADHD and Driving
- 13.19 Stimulants for ‘Off-Label’ Indications
- 13.20 Non-Medical Use of Stimulants
- 13.21 ADHD Medication Clinics
- 13.22 Nurse Prescribing
- 13.23 Specialist Training
- Acknowledgements and Disclosures
- Contents
- Chapter 14 Drugs to Treat Dementia
- Chapter 15 Drugs to Treat Substance Use Disorders
- Chapter 16 Electroconvulsive Therapy and Neuromodulation Therapies
- Part 3 Specific Therapeutic Areas
- Index
Contents
from Chapter 13 - Drugs to Treat Attention Deficit Hyperactivity Disorder (ADHD)
Published online by Cambridge University Press: 29 May 2020
- Seminars in Clinical Psychopharmacology
- College Seminars Series
- Seminars in Clinical Psychopharmacology
- Copyright page
- Contents
- Contributors
- Foreword
- Preface
- Editor’s Note on Nomenclature
- Neuroscience-Based Nomenclature Glossary
- Abbreviations
- Part 1 Basic Science and General Principles
- Part 2 Psychopharmacology of the Main Psychotropic Drug Groups
- Chapter 7 Drugs to Treat Depression
- Chapter 8 Drugs to Treat Anxiety and Insomnia
- Chapter 9 Drugs to Treat Schizophrenia and Psychosis (Dopamine Antagonists and Partial Agonists Other Than Clozapine)
- Chapter 10 Clozapine
- Chapter 11 Lithium
- Chapter 12 Anticonvulsants for Mental Disorders: Valproate, Lamotrigine, Carbamazepine and Oxcarbazepine
- Chapter 13 Drugs to Treat Attention Deficit Hyperactivity Disorder (ADHD)
- 13.1 Introduction
- 13.2 History of Drugs Used to Treat ADHD
- 13.3 Pharmacology and Mechanisms of Action
- 13.4 Legal Status and Licensing of Drugs for Treating ADHD
- 13.5 Writing Prescriptions for Stimulants in the UK
- 13.6 Shared Decision Making/Psychoeducation
- 13.7 Efficacy of Drug Treatment
- 13.8 New Drugs on the ADHD Portfolio
- 13.9 Longer-Term Use of Medications
- 13.10 Placebo Effects in RCTs and Clinical Practice
- 13.11 Adverse Effects of ADHD Medicines and Monitoring
- 13.12 Prescribing Recommendations in ADHD Guidelines
- 13.13 Personalized Drug Selection, Titration and Dose Regimens
- 13.14 Adherence to Medication, Drug Holidays and Flexible Dosing
- 13.15 Annual Review of Medication
- 13.16 Treating ADHD with Co-morbid Disorders
- 13.17 ADHD in Specific Populations
- 13.18 ADHD and Driving
- 13.19 Stimulants for ‘Off-Label’ Indications
- 13.20 Non-Medical Use of Stimulants
- 13.21 ADHD Medication Clinics
- 13.22 Nurse Prescribing
- 13.23 Specialist Training
- Acknowledgements and Disclosures
- Contents
- Chapter 14 Drugs to Treat Dementia
- Chapter 15 Drugs to Treat Substance Use Disorders
- Chapter 16 Electroconvulsive Therapy and Neuromodulation Therapies
- Part 3 Specific Therapeutic Areas
- Index
- Type
- Chapter
- Information
- Seminars in Clinical Psychopharmacology , pp. 392 - 393Publisher: Cambridge University PressPrint publication year: 2020